Join us as we report on the latest developments in immunotherapy from the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition that was hosted virtually December 5-8, 2020. In this episode, we will be speaking to Dr. Laurie Sehn, a Clinical Professor and Researcher with the British Columbia Cancer Centre for Lymphoid Cancer and The University of British Columbia. Immunotherapy was a primary topic at this year’s ASH meeting. Dr. Sehn shares exciting news about the advancements in immunotherapy for Non-Hodgkin Lymphoma. Hear why lymphoma is a great candidate for immunotherapy, how it works, and how a collaboration of researchers from around the world is accelerating the number of new and effective treatments available for lymphoma patients.
Support for this episode provided by Genentech and Pharmacyclics.
Podcast: Play in new window | Download
Subscribe: Apple Podcasts | Google Podcasts | Stitcher | TuneIn | RSS | More
This podcast episode is NOT an official program of the ASH annual meeting.
CLICK HERE to participate in our episode survey.Mentioned on this episode:
- The American Society of Hematology (ASH)
- BC Cancer Agency
- Chimeric Antigen Receptor T-Cell Therapy
- Immunotherapy
- Lymphoma
Additional LLS Support Resources:
The information presented gave a broad picture of how CAR-T cells operate and how they are manipulated to help people like me. It was nice to have some of the gaps in what I already knew filled in and explained.
I have received the latest CART-T cell therapy and it helped me greatly.
Thank you. Today’s podcast on Immunotherapy developments for Lymphomas was very encouraging and informative.